Skip to Content
UW Health SMPH
American Family Children's Hospital
SHARE TEXT

Stroke Clinical Trials

The stroke program at UW Health, University of Wisconsin Hospital and Clinics in Madison, Wisconsin conducts regular clinical trials for patients who are interested and qualified for enrollment.
 
The list below discusses parameters of current clinical trials offered through UW Health's stroke program.
 

RESPECT (Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment)

 
Update: This study is no longer enrolling new subjects
 
Topic: Patent foramen ovale
 
Purpose of study: This is a randomized, active control, blinded, adjudicated outcome clinical trial to investigate whether percutaneous PFO closure is superior to current standard of care medical treatment in the prevention of recurrent embolic stroke.
 
Inclusion Criteria
 

Patients age 18-60 with patent foramen ovale who have had a cryptogenic stroke within the last 270 days.

 

More Information

 

Patients are randomly assigned to best medical therapy or PFO closure with the AMPLATZER PFO Occluder. Best medical therapy treatment options include aspirin alone, Coumadin alone, clopidogrel alone or aspirin combined with dipyridamole.

 

Study contact: Call (608) 263-9602 or amharris@clinicaltrials.wisc.edu

 

 

IRIS (Insulin Resistance Intervention after Stroke Trial)

 
Update: This study is no longer enrolling new subjects
 
Topic: Medical prevention of recurrent stroke
 
Purpose of study: This is a randomized, double-blinded, placebo-controlled trial of pioglitazone (Actos) for the prevention of recurrent stroke and other vascular events. The trial includes subjects who are not diabetic but have insulin resistance as determined by an investigational blood test.
 
A synopsis is available at http://www.strokecenter.org/trials/trialDetail.aspx?tid=596&search_string=iris

 

Study contact: Call (608) 263-9602 or amharris@clinicaltrials.wisc.edu.